



AstraZeneca and Daiichi Sankyo gets FDA approval for its DATROWAY to treat adults with unresectable or metastatic TNBC

(FDA, Approval)



FDA approves AstraZeneca's BAXFENDY, an aldosterone synthase inhibitor, for the treatment of hypertension in combination with other antihypertensives

(FDA, Approval)



Bio-Thera and Accord BioPharma gets FDA approval for IMMGOLIS and IMMGOLIS INTRI, a biosimilar for the treatment of adults with moderately to severely active rheumatoid arthritis and ulcerative colitis

(FDA, Approval)



Merck gets positive CHMP opinion for KEYTRUDA in combination with PADCEV as neoadjuvant treatment and as adjuvant treatment post radical cystectomy for adults with resectable MIBC

(CHMP, Positive Opinion)





(CHMP, Positive Opinion)
AstraZeneca and Daiichi Sankyo's ENHERTU gains positive CHMP opinion as monotherapy for the treatment of adults with unresectable or metastatic HER2-positive solid tumours



(CHMP, Positive Opinion)
CHMP adopts positive opinion for Novo Nordisk's WEGOVY 7.2 mg once-weekly injectable in a single-dose pen for the treatment of obesity



(CHMP, Positive Opinion)
CHMP provides positive opinion for AbbVie's MAVIRET, an oral pangenotypic direct-acting antiviral therapy for the treatment of acute HCV in adults and in children aged 3 years and older



(CHMP, Positive Opinion)
AstraZeneca gains positive positive CHMP opinion for camizestrant in combination with a CDK 4/6 inhibitor for the treatment of adults with (ER)-positive, HER2-negative locally advanced or metastatic breast cancer



(CHMP, Positive Opinion)



Boehringer Ingelheim's JASCAYD obtains positive CHMP opinion for the treatment of adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

(Acquisition)



Neurocrine Biosciences acquires Soleno Therapeutics, strengthening its leadership in endocrinology and rare disease and adding VYKAT XR, INGREZZA and CRENESSITY to its portfolio

(Acquisition)



Gilead acquires Tubulis, maximizing patient benefit through more selective delivery of diverse payloads to tumors along with the addition of TUB-040, TUB-030 to its portfolio

(Phase 3, Results)



Merck's Phase 3 TroFuse-005 trial evaluating sac-TMT met its primary and secondary endpoints, demonstrating improvements in OS and PFS compared with chemotherapy for endometrial cancer

